Navigation Links
Novartis marks World CML Day with update on global research program to evaluate whether Ph+ CML patients can live treatment-free
Date:9/19/2013

tinues," "commitment," "providing support," or similar expressions, or by express or implied discussions regarding potential new indications or labeling for Novartis Ph+ CML products or regarding potential future revenues from such products. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with a Novartis Ph+ CML product to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any Novartis Ph+ CML product will be approved for any additional indications or labeling in any market. Nor can there be any guarantee that any Novartis Ph+ CML product will achieve any particular levels of revenue in the future. In particular, management's expectations regarding such products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; unexpected manufacturing issues; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the infor
'/>"/>
SOURCE Novartis
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
2. Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
3. Leaders from Pfizer, Novartis and J&J Challenge Industry to Disrupt R&D
4. Novartis launches the Cancer Cell Line Encyclopedia to catalog worlds cancer cell lines
5. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
6. Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
7. Spanish researchers writing in cell describe the 9 hallmarks of aging
8. Discovery of gene mutation causing Sturge-Weber syndrome, port-wine stain birthmarks offers new hope
9. Nutra Pharma Patent and Trademarks Published in India
10. Spider Bully for Less: My Cleaning Products Marks Down the Spray for its Christmas Special
11. My Cleaning Products Marks Down Its Bed Bug Bully Price by 20%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... NEW YORK , July 28, 2015 ... "Company"), a diversified life sciences company, today announced that ... authorized shares of common stock of the Company from ... held on July 27, 2015 at the Law Offices ... Meeting").   At the Special Meeting, there were 480,655,929 shares ...
(Date:7/28/2015)... , July 28, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that it has granted to German life sciences ... development and commercialization of biotechnology (collectively, the "Optionee"), ... oral allogenic tumor vaccine technology (the "Technology"), including ... cancer which is ready to enter a Phase ...
(Date:7/27/2015)... FRANKLIN, Tenn. , July 27, ... provider of health care services and one of ... today announced that its parent company and sole ... agreement with Medical Properties Trust, Inc. ("MPT") (NYSE: ... for $900 million in cash.  The transaction is expected to ...
(Date:7/27/2015)... MONTREAL , July 27, 2015   ... that produces sustainable biological accelerators for farmers, has ... Patent and Trademark Office for its patent application ... that accelerate plant growth and enhance yields on ... patent relates to Inocucor,s live IN-M1 microbial consortium ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3
... the Americas -- The Agreement for Europe Will ... of DNA Extraction Kits -- ZyGEM,s Technology Enables ... Automation and High-Throughput Applications -SOLANA BEACH, Calif., and ... Corp. Ltd. and VWR International Europe bvba today ...
... EMERYVILLE, Calif., March 26 Neurobiological Technologies, Inc. (NTI(R)) ... has hired RBC Capital Markets as its exclusive financial ... to enhance shareholder value, including a potential sale of ... Capital Markets to assist us in efficiently determining if ...
... recent study using state-of-the-art genetic testing shows that an all natural skin ... Sirtuin-1, a key anti-aging gene. Until now only Resveratrol, a substance ... to naturally stimulate Sirtuin-1 in humans. Ambra-Lift™ contains no Resveratrol. ... ...
Cached Biology Technology:ZyGEM Corp. and VWR International Europe BVBA Sign Agreement to Distribute Breakthrough DNA Extraction Technology in Europe 2ZyGEM Corp. and VWR International Europe BVBA Sign Agreement to Distribute Breakthrough DNA Extraction Technology in Europe 3ZyGEM Corp. and VWR International Europe BVBA Sign Agreement to Distribute Breakthrough DNA Extraction Technology in Europe 4Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company 2Genomic Study Shows Organic Skin Care Product Activates Key Anti-Aging Gene 2Genomic Study Shows Organic Skin Care Product Activates Key Anti-Aging Gene 3Genomic Study Shows Organic Skin Care Product Activates Key Anti-Aging Gene 4
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 30, 2015 after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... When investigating cancer cells, researchers discovered numerous peculiarities: ... genes are overactive. Do these characteristics have a relation ... inactivate growth brakes or are they just a whim ... scientists perform what are called loss-of-function analyses. They knock ...
... the University of Hawaii Cancer Center and The Queen,s ... from the National Cancer Institute to develop novel methods ... analysis of gene expression and imaging data of the ... a research scientist at the UH Cancer Center, and ...
... An extreme form of pregnancy-related nausea and vomiting known ... of women each year and can lead to hospitalization and ... the only victims. A joint study by ... children whose mothers suffered from HG while carrying them were ...
Cached Biology News:A question of gene silencing 2Hawaii receives funding for liver cancer research 2Extreme morning sickness could lead to lifelong emotional, behavioral disorders in kids 2
... Anti-NY-ESO-1, clone E978 ... : NM_001327 Immunogen ... protein Formulation: mouse ascites ... Quality Assurance: routinely evaluated ...
... to Opsin 1 ( Abpromise for all ... peptide: YEDSTHASIFTYT, corresponding to amino acids 14/26 of ... corresponding to amino acids 18/30 of tiger red ... immunogen. Entrez Gene ID: ...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Request Info...
Biology Products: